A mobile fertility app is the first ever digital contraceptive device to win FDA marketing approval. But reports of unwanted pregnancies and investigations in Europe have raised questions about marketing what is essentially a health monitor as a…
Many Democratic congressional hopefuls are making healthcare their top talking point for the upcoming midterm elections, which is not surprising given the low unemployment rate. The early donations from political action groups lean toward the…
The healthcare industry saw fewer bankruptcies in the second quarter of 2018 compared with the first, according to law firm Polsinelli, breaking with eight quarters of record or near-record highs. But one report author doesn’t expect the lull to…
Teva Pharmaceutical’s product is the first direct generic copy of the EpiPen, the life-saving automatic epinephrine injector that fueled a national debate on rising pharmaceutical prices.
NYU School of Medicine will provide free tuition to all current and future students to alleviate the burden of crippling debt on physicians. It’s the first major medical school in the U.S. to provide free education to all students.
As scrutiny tightens on drug middlemen and the significance of their role in spiking drug costs within Medicare Part D, health insurers are hitting back with data that show the most expensive drugs offer the lowest rebates.
A special National Institutes of Health oversight panel will no longer review all gene therapy applications and will instead take on a broader advisory role, as the treatment quickly becomes an established form of medical care with no extraordinary…
Best Buy is the latest consumer company to step further into healthcare. The consumer tech retailer will buy GreatCall, maker of mobile devices aimed at the aging population.
Harvard Pilgrim Health Care saw a big jump in net income during the second quarter of 2018, which wrapped up weeks after the health plan’s CEO abruptly resigned over unspecified behavior.
Ohio’s Medicaid department is directing its managed-care organizations to quit their contracts with pharmacy benefit managers because of opaque pricing practices and strike up new arrangements with transparent vendors.